REGN FY2026 EPS Forecast Lifted by Cantor Fitzgerald

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) – Analysts at Cantor Fitzgerald upped their FY2026 earnings estimates for Regeneron Pharmaceuticals in a report released on Thursday, October 9th. Cantor Fitzgerald analyst C. Gould now anticipates that the biopharmaceutical company will post earnings of $32.12 per share for the year, up from their previous forecast of $30.33. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $35.92 per share.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. During the same quarter in the previous year, the company earned $11.56 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 3.6% on a year-over-year basis.

Several other brokerages have also recently issued reports on REGN. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price objective on the stock. in a report on Friday, August 1st. Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Finally, Morgan Stanley cut their price objective on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a report on Friday. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $817.88.

Get Our Latest Research Report on REGN

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $557.73 on Monday. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $1,024.36. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The company’s 50-day moving average is $573.67 and its 200 day moving average is $563.46. The stock has a market capitalization of $59.11 billion, a P/E ratio of 14.06, a P/E/G ratio of 1.80 and a beta of 0.31.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.87%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Marietta Wealth Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 30.2% in the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company’s stock worth $6,836,000 after buying an additional 2,501 shares in the last quarter. Sepio Capital LP lifted its stake in shares of Regeneron Pharmaceuticals by 33.1% in the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock worth $2,150,000 after buying an additional 842 shares in the last quarter. Founders Capital Management LLC lifted its position in Regeneron Pharmaceuticals by 7.0% during the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock valued at $4,344,000 after purchasing an additional 538 shares during the period. PGGM Investments lifted its position in Regeneron Pharmaceuticals by 159.7% during the second quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock valued at $44,308,000 after purchasing an additional 51,900 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in Regeneron Pharmaceuticals by 3.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock valued at $16,255,000 after purchasing an additional 955 shares during the period. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

(Get Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Stories

Earnings History and Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.